Clinical Trials Directory

Trials / Sponsors / Xiaorong Dong

Xiaorong Dong

Academic / Other · 7 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingFirst Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Small Cell Lung Cancer Extensive Stage
Phase 22024-03-07
UnknownCirculating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Met
Carcinoma, Non-Small-Cell Lung, Brain Metastases
—2023-02-13
UnknownAdebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment
Non-small Cell Lung Cancer
Phase 22022-12-01
UnknownAnlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction
NSCLC, Anlotinib, PD-1/L1 Inhibitor
Phase 22020-04-01
UnknownAnalysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembroli
Gut Microbiota, NSCLC, Pembrolizumab
Phase 1 / Phase 22020-04-01
UnknownSRS Sequential Sindilimab in Brain Metastasis of NSLSC
NSCLC Stage IV, Brain Metastases, SRS
Phase 22019-11-01
UnknownThe Role of Microbiota on the Development of Lung Cancer
NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III
—2018-01-30